Department of Food and Nutritional Sciences, The University of Reading, Reading, UK.
Clasado Research Services, Thames Valley Science Park, Reading, UK.
Neurogastroenterol Motil. 2018 Nov;30(11):e13440. doi: 10.1111/nmo.13440. Epub 2018 Aug 15.
Prebiotics exert beneficial effects upon gastrointestinal (GI) environment, but this is not always accompanied with a positive effect on GI symptoms. B-GOS® is a prebiotic with high selectivity toward bifidobacteria and a variety of other beneficial effects in humans. Here, we investigated its effect on GI symptoms in adults who suffer with bloating, abdominal pain, and flatulence.
In a double-blind, placebo-controlled, crossover study, 83 subjects from the general population who presented with GI symptoms during screening period and had a predicted probability of functional bowel disorder of more than 75% were randomized to receive either a placebo or the B-GOS® treatment (2.75 g/d). Subjects were screened for the presence of GI symptoms for 1 week, they consumed the treatments for 2 weeks, and then went through a 2-week washout period, before switching to the other treatment for the final 2 weeks. GI symptoms, bowel movements, and stool consistency were assessed in daily and weekly questionnaires. Quality of life was assessed weekly and depression and anxiety at the end of each treatment period.
B-GOS® resulted in significantly (P < 0.001) lower scores for bloating, flatulence, and abdominal pain both from baseline and placebo at the end of first week. The effect was sustained at the end of second week. It had no effect on the number of bowel movements, consistency of stools, quality of life, or mood throughout the study.
Results suggest that B-GOS® could possibly be used in the management of bloating, flatulence, or abdominal pain and warrant further investigation.
益生菌对胃肠道（GI）环境有有益影响，但这并不总是伴随着对 GI 症状的积极影响。B-GOS®是一种对双歧杆菌具有高选择性的益生元，在人类中具有多种其他有益作用。在这里，我们研究了它对患有腹胀、腹痛和胀气的成年人 GI 症状的影响。
在一项双盲、安慰剂对照、交叉研究中，从一般人群中随机选择 83 名在筛选期间出现 GI 症状且功能性肠病预测概率超过 75%的受试者，接受安慰剂或 B-GOS®治疗（2.75g/d）。受试者在筛选期内连续 1 周记录 GI 症状，接受治疗 2 周，然后进入 2 周洗脱期，最后再接受另一种治疗 2 周。每天和每周评估 GI 症状、排便次数和粪便稠度。每周评估生活质量，在每个治疗期末评估抑郁和焦虑。
B-GOS®在第一周结束时，与基线和安慰剂相比，腹胀、胀气和腹痛的评分显著降低（P<0.001）。这种效果在第二周结束时仍然持续。它对排便次数、粪便稠度、生活质量或情绪没有影响。
结果表明，B-GOS®可能可用于管理腹胀、胀气或腹痛，并值得进一步研究。
